Suspension of trading

Akero Therapeutics, Inc.

AKRO

US00973Y1082

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 01:00:00 09/12/2025 +04			5-day change	1st Jan Change
54.65 ^USD	+0.18%		-.--%	-

12-11	Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from S&P Biotechnology Select Industry Index	CI
12-11	Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from S&P Global BMI Index	CI

Akero Therapeutics, Inc.(NasdaqGM:AKRO) dropped from Russell 2000 Index

Published on 12/10/2025

S&P Capital IQ

AKERO THERAPEUTICS, INC.

+0.18%

RUSSELL 2000

+1.48%

Akero Therapeutics, Inc.(NasdaqGM:AKRO) dropped from Russell 2000 Index

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	AKERO THERAPEUTICS, INC.	54.65USD	+0.18%	-.--%	4.5B
	RUSSELL 2000	2,684.51PTS	+1.48%	+1.14%	-

Latest news about Akero Therapeutics, Inc.

12-11	Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from S&P Biotechnology Select Industry Index	CI
12-11	Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from S&P Global BMI Index	CI
12-11	Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from S&P TMI Index	CI
12-10	Akero Therapeutics, Inc.(NasdaqGM:AKRO) dropped from Russell Small Cap Comp Growth Benchmark	CI
12-10	Akero Therapeutics, Inc.(NasdaqGM:AKRO) dropped from Russell 3000E Growth Benchmark	CI
12-10	Akero Therapeutics, Inc.(NasdaqGM:AKRO) dropped from Russell 3000 Growth Benchmark	CI
12-10	Akero Therapeutics, Inc.(NasdaqGM:AKRO) dropped from Russell 2500 Growth Benchmark	CI
12-10	Akero Therapeutics, Inc.(NasdaqGM:AKRO) dropped from Russell 2000 Growth Benchmark	CI
12-10	Akero Therapeutics, Inc.(NasdaqGM:AKRO) dropped from Russell 2500 Growth-Dynamic Index	CI
12-10	Akero Therapeutics, Inc.(NasdaqGM:AKRO) dropped from Russell 2000 Growth-Dynamic Index	CI
12-10	Akero Therapeutics, Inc.(NasdaqGM:AKRO) dropped from Russell 2500 Dynamic Index	CI
12-10	Akero Therapeutics, Inc.(NasdaqGM:AKRO) dropped from Russell 2000 Dynamic Index	CI
12-10	Akero Therapeutics, Inc.(NasdaqGM:AKRO) dropped from Russell 2500 Growth Index	CI
12-10	Akero Therapeutics, Inc.(NasdaqGM:AKRO) dropped from Russell 3000 Growth Index	CI
12-10	Akero Therapeutics, Inc.(NasdaqGM:AKRO) dropped from Russell Small Cap Comp Growth Index	CI
12-10	Akero Therapeutics, Inc.(NasdaqGM:AKRO) dropped from Russell Small Cap Completeness Index	CI
12-10	Akero Therapeutics, Inc.(NasdaqGM:AKRO) dropped from Russell 2000 Growth Index	CI
12-10	Akero Therapeutics, Inc.(NasdaqGM:AKRO) dropped from Russell 2500 Index	CI
12-10	Akero Therapeutics, Inc.(NasdaqGM:AKRO) dropped from Russell 3000 Index	CI
12-10	Akero Therapeutics, Inc.(NasdaqGM:AKRO) dropped from Russell 2000 Index	CI
12-09	Novo Nordisk A/S (CPSE:NOVO B) completed the acquisition of Akero Therapeutics, Inc..	CI
12-09	Novo Nordisk Concludes Up to $5.2 Billion Takeover of Akero Therapeutics	MT
12-09	Akero Therapeutics, Inc. Announces Board Changes	CI
12-09	Novo Nordisk Completes Acquisition of Akero Therapeutics	FW
12-09	Novo Nordisk completes acquisition of Akero Therapeutics	RE

Chart Akero Therapeutics, Inc.

Duration

Period

AKRO: Dynamic Chart

Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.

Employees

Sector

Biotechnology & Medical Research

Calendar

03-12 - Q4 2025 Earnings Release (Projected)

More about the company